Expressão do Ki67 e dos Receptores de Estrógeno e Progesterona em Gliomas
DISSERTAÇÃO DE MESTRADO – Cléciton Braga Tavares
53
6. CONCLUSÕES
Expressão do Ki67 e dos Receptores de Estrógeno e Progesterona em Gliomas
54
Neste estudo:
1. A expressão da proteína Ki-67 foi significantemente maior nos astrocitomas de alto grau em comparação com os de baixo grau.
2. Somente os astrocitomas de baixo grau mostraram expressão do RE, com uma diferença estatisticamente significante em comparação com os de alto grau.
3. A expressão do receptor de progesterona foi similar entre os astrocitomas de baixo e alto grau.
Expressão do Ki67 e dos Receptores de Estrógeno e Progesterona em Gliomas
DISSERTAÇÃO DE MESTRADO – Cléciton Braga Tavares
55
REFERÊNCIAS
Expressão do Ki67 e dos Receptores de Estrógeno e Progesterona em Gliomas
56
ASSIMAKOPOULOU M. et al. Does Sex Stereoid Receptor Status Have any
Prognostic or Predictive Significance in brain Astrocytic Tumors?ClinNeuropathol, v.17, p.27-34, 1998.
ATIF F.; YOUSUF S.; STEIN D.G. Anti-tumor effects of progesterone in human glioblastomamultiforme: Role of PI3K/Akt/mTOR signaling. Journal of Steroid Biochemistry & Molecular Biology, v.146, p.62–73, 2015.
BATISTATOU A. et al. Estrogen receptor beta (ERb) protein expression correlates with BAG-1 and prognosis in brain glial tumours. Journal of Neuro-Oncology, v. 77, p.17–23, 2006.
BATISTATOU, A. et al. Estrogen Receptor Beta (Erb) is Expressed in Brain
Astrocytic Tumors and Declines with Dedifferentiation of The Neoplasm. J Cancer Res ClinOncol, v.130, p. 405–410, 2004.
BERNY W. Analysis of expression of estrogen (ER) and progesterone receptors (PR) in brain glial tumors and its correlation with expression of p53 protein and
proliferating cell nuclear antigen (PCNA). NeurolNeurochir Pol, v.38 p.367-371, 2004.
CABRERA-MUNOZ E. et al. Regulation of progesterone receptor isoforms content in human astrocytoma cell lines.Journal of Steroid Biochemistry & Molecular
Biology, v.113, p. 80–84, 2009.
CABRERA-MUÑOZ E.;HERNÁNDEZ-HERNÁNDEZ O.T.; CAMACHO-ARROYO I.
Role of progesterone in human astrocytomas growth.Curr Top Med Chem, v.11, p.1663-1667, 2011.
CARROLL R.S. et al. Steroid Hormone Receptors in Astrocytic Neoplasm.Neurosurgery, v.37, p. 496-504, 1995.
CHECK J.H. et al. Evidence that Mifepristone, a progesterone receptor antagonist, can cross the blood brain barrier and provide palliative benefits for
glioblastomamultiforme grade IV.Anticancer Res, v. 34, p.2385-2388, 2014.
CORK D.M.; Lennard T.W.; Tyson-Capper A.J. Alternative splicing and the progesterone receptor in breast cancer. Breast Cancer R, v.10,p. 207, 2008.
DEBNAM, J.M. et al. Radiology of Brain Tumors: Structure and Physiology. In:
DeMONTE, F. et al. Tumors of the Brain and Spine. United States of America:
Spinger, 2007. p. 37-52.
DUEÑAS JIMÉNEZ J.M, et al. Aromatase and estrogen receptor alpha mRNA expression as prognostic biomarkers in patients with astrocytomas.J Neurooncol, v.119, p. 275-284, 2014.
EVANS S.M. et al. Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding.Cancer Res, v.64, p.1886–1892, 2004.
Expressão do Ki67 e dos Receptores de Estrógeno e Progesterona em Gliomas
DISSERTAÇÃO DE MESTRADO – Cléciton Braga Tavares
57
GERDES J. et al. Production of a Mouse Monoclonal Antibody Reactive with a Human Nuclear Antigen Associated with Cell Proliferation. Int J Cancer,v.31, p.13-20, 1983.
GERMÁN-CASTELÁN L.; MANJARREZ-MARMOLEJO J.; GONZÁLEZ-ARENAS A.
Progesterone Induces the Growth and Infiltration of Human Astrocytoma Cells Implanted in the Cerebral Cortex of the Rat.BioMed Research International, p.1-8, 2014.
GLANTZ SA. Primer in Biostatistics. 5.ed. New York: McGraw-Hill, 2002.
GONZALEZ-AGUERO G, et al. Progesterone Receptor Isoforms Expression Pattern in Human Astrocytomas. Brain Research Bulletin, v.56, p.43-48, 2001.
GONZÁLEZ-ARENAS A, et al. PKCα and PKCδ Activation Regulates Transcriptional Activity and Degradation of Progesterone Receptor in Human Astrocytoma Cells.
Endocrinology, v.156, p.1010–1022, 2015.
GONZÁLEZ-ARENAS A.et al. Estradiol increases cell growth in human astrocytoma cell lines through ER activation and its interaction with SRC-1 and SRC-3
coactivators. Biochimica et Biophysica Acta, v.1823, p. 379–386, 2012.
HABBERSTAD A.H.; GULATI S; TORP S.H. Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIa in human
anaplastic astrocytomas an immunohistochemical study. Diagnostic Pathology.v.6, p.43, 2011.
HASSANZADEH P.; ARBABI E. The Effects of Progesterone on Glial Cell Line-derived Neurotrophic Factor Secretion from C6 Glioma Cells.Iran J Basic Med Sci, v.15, p.1046-1052, 2012.
HERNÁNDEZ-HERNÁNDEZ O. T, GONZÁLEZ-GARCÍA T. K,
CAMACHO-ARROYO I. Progesterone receptor and SRC-1 participate in the regulation of VEGF, EGFR and Cyclin D1 expression in human astrocytoma cell lines.Journal of Steroid Biochemistry & Molecular Biology, v.132, p.127–134, 2012.
HERNANDEZ-HERNANDEZ O.T. et al. Progesterone and Estradiol Effects on SRC-1 and SRC-3 Expression in Human Astrocytoma Cell Lines.Endocrinology, v.37, p.194-200, 2010.
HLAVATY J. et al. Expression of Progesterone Receptor Membrane Component 1 (PGRMC1), Progestin and AdipoQ Receptor 7 (PAQPR7), and Plasminogen Activator Inhibitor 1 RNA-Binding Protein (PAIRBP1) in Glioma Spheroids In Vitro.BioMed Research International, v.2016, p. 1-12, 2016.
HO V.K.Y. et al. Changing incidence and improved survival of gliomas.European Journal of Cancer, v.50, p.2309–2318, 2014.
HSU D.W. et al. Use of MIB-1 (Ki-67) Immunoreactivity in Difeferentianing Grade II and Grade III gliomas.J NeuropatholExpNeurol, v.56, p.857-865, 1994.
Expressão do Ki67 e dos Receptores de Estrógeno e Progesterona em Gliomas
58
HU X. et al. Expression of p53, epidermal growth factor receptor, Ki-67 and O6-methylguanine-DNA methyltransferase in human gliomas. Oncology Letters, v.6, p 130-134, 2013.
JIMENEZ J.M.D. et al. Aromatase and estrogen receptor alpha mRNA expression as prognostic biomarkers in patients with astrocytomas.J Neurooncol, V.119, p.275–
284, 2014.
JOHANNESSEN A.L.; TORP S.H. The Clinical Value of Ki-67/MIB-1 Labeling Index in Human Astrocytomas.PathologyOncologyResearch, v.12, p.143-147, 2006.
JUNQUEIRA, L.C.; CARNEIRO, J. Histologia Básica. 9.ed. Rio de Janeiro:
Guanabara Koogan, 1999.
KABAT, G.C.; ETGEN, A.M.; ROHAN T.E. Do Steroid Hormones Play a Role in the Etiology of Glioma? Cancer Epidemiol Biomarkers Prev, v.19, p. 2421-2427, 2010.
KARAMITOPOULOU, E. et al. Ki-67 Immunoreactivity in Human Central Nervous System Tumors: a Study with MIB-1 Monoclonal Antibody on Archival Material.
ActaNeuropathol, v. 87.p.47-54, 1994.
KELES, G.E. et al. Low-Grade Astrocytomas. In: TONN, J.C. et al. Neuro-Oncology of CNS Tumors. 1. ed. Germany: Springer, 2006. p. 104-117.
KHALID H. et al. Immunohistochemicalanalysisof progesterone receptor and Ki-67 labeling index in astrocytictumors. Cancer, v.11, p.2133-2140, 1997.
KOSTANTINOPOULOS P.A. et al. Oestrogen Receptor beta (ERb) is Abundantly Expressed in Normal Colonic Mucosa, but Declines in Colon Adenocarcinoma Paralleling the Tumors Dedifferentiation. Eur J Cancer, v.39, p.1251–12458, 2003.
LIU C. et al. Expression of estrogen receptors, androgen receptor and steroid receptor coactivator-3 is negatively correlated to the differentiation of astrocytic tumors.Cancer Epidemiology, v.38, p. 291–297, 2014.
PATEL, S. et al. Phase I Clinical Trial Assessing Temozolomide and Tamoxifen with Concomitant Radiotherapy for Treatment of High-Grade Glioma.I. J. Radiation Oncology Biology Physics, v.82, p.739-742, 2012.
POLLACK, F. et al. Effect of Tamoxifen on DNA Synthesis and Proliferation of
Human Malignant Glioma Lines in Vitro.Cancer Research, v.50, p.7134-7138, 1990.
RATHI K.R.; RADOTRA B.D.; KHOSLA V.K. Proliferative Index in AstrocyticTumours. Indian J PatholMicrobiol, v.50, p.754‑758, 2007.
REIFENBERGER, G. et al. Pathology and Classification of Tumors of the Nervous System. In: TONN, J.C. et al. Neuro-Oncology of CNS Tumors. 1. ed. Germany:
Springer, 2006. p. 104-117.
ROBINS, H.I. et al. Phase 2 Trial of Radiation plus High-dose Tamoxifen for
GlioblastomaMultiforme: RTOG protocol BR-0021. Neuro-Oncology, p.47-51, 2006.
Expressão do Ki67 e dos Receptores de Estrógeno e Progesterona em Gliomas
DISSERTAÇÃO DE MESTRADO – Cléciton Braga Tavares
59
ROSAL A.M.; DA SILVA B.B. Evaluation of estrogen and progesterone receptors in non-neoplasic breast tissue of women of reproductive age explosed to tamoxifen and raloxifene: a randomized, double-blind study.Breast Cancer Res Treat, v.125, p.797-801, 2011.
SAHA R. et al. Expression of phosphatase and tensin homolog, epidermal growth factor receptor, and Ki-67 in astrocytoma: A prospective study in a tertiary care hospital. Indian J. MedPaediatr, v.35, p.149-55, 2014.
SAREDDY G.R. et al. Therapeutic significance of estrogen receptor beta agonists in gliomas.Mol. Cancer Ther, v.11, p.1174–1182, 2012.
SIEGAL T. Clinical Impact of Molecular Biomarkers in Gliomas.Journal of Clinical Neuroscience, v.22, p.437-444, 2015
SKJULSVIK A.J. et al. Ki-67/MIB-1 Immunostaining in a Cohort of Human Gliomas.Int J ClinExpPathol, v.12, p.8905-8910, 2014.
TANG, P.A. et al. A Phase II Study of Carboplatin and Chronic High-Dose Tamoxifen in Patients with Recurrent Malignant Glioma.Journal of Neuro-Oncology, v.78, p.
311–316, 2006.
TAVARES C.B. et al. Expression of estrogen and progesteronereceptors in astrocytomas: a literature review. Clinics.v.71 p.481-486, 2016.
THOTAKURA, M.; TIRUMALASETTI, N.; KRISHNA, R. Role of Ki-67 labeling index as an adjunct to the histopathological diagnosis and grading of astrocytomas. J Can Res Ther, v.10, p.641-645, 2014.
THUY M.N.T. et al. A novel literature-based approach to identify genetic and molecular predictors of survival in glioblastomamultiforme: Analysis of 14,678 patients using systematic review and meta-analytical tools. Journal of Clinical Neuroscience, v.22, p.785–799, 2015.
TONN, J.C. et al. Neuro-Oncology of CNS Tumors.1. ed. Germany: Springer, 2006
UEHARA K. et al. Patterns of failure after multimodal treatments for high-grade
glioma: effectiveness of MIB-1 labeling index. Radiation Oncology, v.7, p.104, 2012.
UEMATSU M. et al. Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index. Journal of Neuro-Oncology, v. 72, p. 231–238, 2005.
VALADEZ-COSMES P. et al. Expression and hormonal regulation of membrane progesterone receptors in human astrocytoma cells.Journal of Steroid
Biochemistry & Molecular Biology,v. 154, p.176–185, 2015.
WEN-JIE C. et al. Ki-67 is a Valuable Prognostic Factor in Gliomas: Evidence from a Systematic Review and Meta-analysis. Asian Pacific Journal of Cancer
Prevention, v.16, p.411-420, 2015.
Expressão do Ki67 e dos Receptores de Estrógeno e Progesterona em Gliomas
60
WEINGART, J.D.; MCGIRT, M.J.; BREM, H. High-Grade
Astrocytoma/Glioblastoma.In: TONN, J.C. et al. Neuro-Oncology of CNS Tumors.
1. ed. Germany: Springer, 2006. p. 104-117.
WENJUN LIA. et al. Involvement of estrogen receptor b5 in the progression of glioma. Brain Research, v.1503, p. 97–107, 2013.
YAMASHITA Y. et al. CDC25A mRNA levels significantly correlate with Ki-67 expression in human glioma samples.J Neuroncol, v.100, p.43–49, 2010.
ANEXOS
Expressão do Ki67 e dos Receptores de Estrógeno e Progesterona em Gliomas
DISSERTAÇÃO DE MESTRADO – Cléciton Braga Tavares
61
ANEXO A- Parecer de aprovação do Comitê de Ética em Pesquisa da Universidade Federal do Piauí.
UNIVERSIDADE FEDERAL DOPIAUÍ - UFPI
DADOS DO PROJETO DE PESQUISA
Título da Pesquisa: Biomarcadores Moleculares em Mulheres com Neoplasia Mamária.
Pesquisador: Benedito Borges da Silva
Versão: 2 ÁreaTemática:
CAAE: 43447015.8.0000.5214
InstituiçãoProponente: FUNDACAO UNIVERSIDADE FEDERAL DO PIAUI
Patrocinador Principal: Financiamento Próprio DADOS DO PARECER
Número do Parecer: 1.380.140
Considerações sobre os Termos de apresentaçãoobrigatória:
A proposta apresenta os componentes básicos exigidos por uma pesquisa acadêmica, referencial teórico que dará sustentação ao estudo, bem como os aspectos éticos do estudo, cronograma e orçamento afirmando ser financiada com recursos próprios.
Os objetivos estão coerentes com a proposta de estudo. O coordenador é docente da UFPI com experiência na temática evidenciada e se compromete cumprir os termos da Resolução CNS nº 466/12 - e zelar pela privacidade e confidencialidade dos dados.
Recomendações:
Sem recomendações
Conclusões ou Pendências e Lista de Inadequações:
Sem pendências Situação do Parecer:
Aprovado
Necessita Apreciação da CONEP:
Não.